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Abstract Smoking is one of the sources of thallium which is
considered as a toxic heavy metal. The aim of this study was
to determine urinary thallium levels and related variables in
smokers, compared to a control group. The study was con-
ducted on 56 participants who had smoked continuously dur-
ing the year before they were referred to Kashan Smoking
Cessation Clinic. Fifty-three nonsmokers who were family
members or friends of the smokers were selected as the control
group. Urinary thallium was measured in both groups
(n = 109) using atomic absorption spectrophotometry. The
mean value (with SD) for urinary thallium in the smokers
(10.16 ± 1.82 μg/L) was significantly higher than in the con-
trol group (2.39 ± 0.63 μg/L). There was a significant rela-
tionship between smoking duration and urinary thallium
levels (P = 0.003). In a subgroup of smokers who was
addicted to opium and opium residues (n = 9), the mean level
of thallium (37.5 ± 13.09 μg/L) was significantly higher than
in the other smokers (4.93 ± 4.45; P = 0.001). Multiple regres-
sion analysis showed opioid abuse, insomnia, and chronic
obstructive pulmonary disease (COPD), together were strong
predictors of urinary thallium levels in smokers. There was no
significant difference in thallium level in hookah smokers
(P = 0.299) or in those with COPD compared to other smokers
(P = 0.375). Urinary thallium levels of smokers with clinical
signs of depression, sleep disorders, memory loss, and sweat-
ing were higher than those of smokers without these signs.
Since thallium, as other toxic metals is accumulated in the
body, and cigarette smoking also involves carcinogenic expo-
sures and health hazards for passively exposed people, the
need for cigarette control policies is emphasized.
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Introduction
There are 15.1 billion smokers in the world, and 8% of this
abuse is related to developing countries based on World
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Health Organization (WHO) statistics. WHO reported the
prevalence of cigarette consumption in Iran to be 18.5%
among adult men and 0.2% among women in 2010.
Furthermore, they estimated that these figures would reach
19% among men and 10% among women in 2025. Nine per-
cent of the total population in Iran was anticipated to be
smokers in 2025 [1, 2]. WHO also estimated that smoking
(cigarette and smoke) is currently responsible for death of 6
million people worldwide; this rate includes 600,000 people
who are also estimated to die from the effects of second-hand
smoke. And a third of all cancer deaths are associated with
smoking [3, 4]. Tobacco contains more than 4000 different
toxic substances, including tobacco-specific nitrosamines,
carcinogens, heavy metals, and polyaromatic hydrocarbons.
Among the toxic metals are cadmium, thallium, and lead,
which can give rise to heart disease, as well as renal and
respiratory problems, hair loss and dermatology, and obesity
in females upon long-term exposure [3–12]. The occurrence
of thallium in the lithosphere is 100 ppm. Thallium can be
considered as one of the most toxic metals [13]. In the past,
thallium compounds have been used as rat poisons and insec-
ticides, but today, they have been banned due to their toxicity
and harmful effects on humans. This metal is now used as
radioisotope forms for medical purposes, i.e., to visualize
scintigraphically the circulation in the heart and to trace mel-
anoma worsening [14, 15]. The most frequent reasons for
thallium intoxication are unintentional or deliberate use in
industrial settings. The amount estimated to cause thallium
poisoning is 8 mg/kg body weight, and an amount of 10–
15 mg/kg is considered to be life-threatening. Thallium in
such doses may lead to death after few days—due to kidney
failure, serious symptoms from the nervous system, and heart
disorders. Although the mechanisms of thallium toxicity are
essentially unknown, two proposed mechanisms can be men-
tioned: First, thallium like lead and mercury is strongly bond
to sulfhydryl groups on proteins, thereby disrupting the func-
tions of the kidneys and heart and the nervous and digestive
systems. Secondly, thallium can replace potassium in human
body because of its similarity with potassium ions, and thus,
thallium can be accumulated intracellularly where it hits and
disrupts vital proteins and enzymes [15–17]. Gastroenteritis,
polyneuropathy, and hair loss are described as main symptoms
of thallium poisoning, but other symptoms may arise depend-
ing on exposure dose and duration [18]. Any amount of thal-
lium is abnormal in the human body [13]; according to
Ćurković et al. [19], the normality cut-off point concentration
of thallium in normal population is considered to be less than
5 μg/L. Thallium compounds are considered to have terato-
genic properties, even in relatively low doses [20–22]. Also,
various drug abuses, especially heroin and opium abuse, can
involve thallium exposure with neurologic, gastrointestinal,
and skin symptoms [23–25]. The Agency of Toxic
Substances and Disease Registry in a report on toxicological
profile of thallium has shown that smoking is one of the thal-
lium sources and they suspect that the amount of thallium in
smokers is significantly increased as compared to nonsmokers
[26]. According to their report, thallium can be detected in the
urine for 2 months after exposure [26].
The present study was precipitated by concerns related to
the widespread use of cigarettes together with the presumed
thallium exposure resulting from cigarette smoking.
Materials and Methods
This was a case-control study. This research was carried out in
accordance with the Declaration of Helsinki, and informed
consent was taken from all subjects. Fifty-six smokers who
were referred to Kashan Smoking Cessation Outpatient
Clinic, with an age range of 23–77 years, were consecutively
enrolled in the study. And 53 nonsmokers, who were relatives
or friends of the smokers and comparable to the smokers in
terms of demographic variables (age, sex, and socioeconomic
terms), were selected. The smokers had a smoking history of
at least 1 year and had smoked continuously during the last
year. The control group included people who had no history of
smoking. People with thallium exposure in their occupational
history such as battery makers, soldiers, or painters were ex-
cluded in order to control factors affecting thallium level.
Samples and demographic information were collected
within 4 months. Given that thallium is slowly removed from
body and the maximum amount is excreted in the urine and
lesser amount is excreted in the stool [26], urine samples were
considered as good indices of thallium exposure.
Urine samples were collected from both groups and were
stored at − 20 °C until analysis. Analyses of all samples were
conducted by using atomic absorption spectrometry (Perkin
Elmer Model 3030 with HGA 400 Programmer) in the toxi-
cology laboratory [27]. An aliquot (0.5 ml) of the urine was
put in a test tube and 0.5 ml of sulfuric acid 1% and 0.5 cc of
nitric acid 0.2%, and 10 ml of Triton X-100 were added. After
centrifugation, 25 μL of the highly transparent supernatant
was injected into the graphite tube. Standard, blank, and con-
trol samples were prepared in a similar way. Thermal program
was selected in atomic absorption spectrometry as follows:
130 °C was used for drying, 300 °C for organic compounds
for incinerate, and 800 °C for inorganic compounds.
Atomization was performed at 1700 °C [28, 29]. Detection
limit was assessed to be 0.2 μg/L; precision (3.65%) and ac-
curacy (97.4%) were determined by analyses and repeated
measurements of thallium standard control samples
(SERONORM urine trace element level 2, lot 1011645)
[30]. Intra-day and day-to-day tests were carried out in order
to verify accuracy and repeatability of the system.
All patients were given information on the study and
agreed to participate on a consent form before inclusion. The
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study was approved by the committee for ethics at the Kashan
University of Medical Sciences (KAUMS.REC.20).
Statistical Analysis
Statistical analysis of data was performed by using the 17
SPSS software. Quantitative data were analyzed using t test
on data with normal distribution and equality of variances in
both groups. Nonparametric Mann-Whitney U test was used
in the absence of parametric statistical preconditions.
Qualitative data were analyzed using chi-square test, and re-
lationship between variables was analyzed using Pearson or
Spearman correlation. A P value less than 0.05 was consid-
ered throughout the study as the indication of significant dif-
ference (significance level) between groups. Multiple regres-




At start, 120 subjects were recruited to the two groups: 60
patients constituted the smoker group and 60 patients consti-
tuted the control group. A total of 109 subjects signed the
consent form and thus remained included: 56 smokers and
53 controls. The mean age and SD of the smoker group was
44.98 ± 15.62 years (range 23–77 years) and that of the con-
trol group 42 ± 18.30 years (range 18–89 years). Cigarette
consumption of the smoking group during the year was in
average (number per day) 21.48 ± 8.15 cigarettes (range 8–
40 cigarettes). Also, in the smoking group, 36 patients
(64.3%) had a history of family consumption, 29 patients
(51.8%) were cigarette consumers of an Iranian brand
(Bahman, Boston, Zika), 20 patients (35.7%) consumed hoo-
kah, 11 patients (19.64%) were with COPD, and 9 patients
(16%) consumed opium and opium residues in addition to
smoking.
Clinical Symptoms
Thirty-four patients of the smoking group had neurological
symptoms (60.7%), 5 patients had skin symptoms (8.9%),
and 4 patients had gastrointestinal symptoms (7.1%), and the
others were asymptomatic.
With regard to neurological symptoms among the smokers,
the frequency of aggressiveness was 57% (n = 56), and weak-
ness and jerking movements was observed in 50 and 49%,
respectively, and tremor (45%), paresthesia (45%), fatigue
(43%), headache (42%), insomnia (41%), memory deficits
(38%), blurred vision (34%), depression (29%), emotional
liability (27%), vertigo (25%), tinnitus (20%), ataxia (13%),
delirium-psychosis-coma (13%), choreoathetosis (9%), and
seizures (6%) were also observed, particularly in the subgroup
with combined abuse of cigarettes and narcotics.
With regard to dermatological symptoms, scalp hair loss
was observed in 38%, and sweating (29%), dry skin (27%),
body hair loss (16%), rashes (11%), Mees’ lines (5%), palmar
erythema (3%), and acne (2%) were also reported.
Gastrointestinal symptoms included constipation (32%),
abdominal pain (25%), nausea (16%), vomiting (7%), and
diarrhea (4%).
Thallium levels in smokers (N = 56) with symptoms of
memory deficits (t = 3.06, P = 0.004), insomnia (t = 2.01,
P = 0.049), depression (t = 3.34, P = 0.002), and sweating
(t = 2.08, P = 0.042) were higher than in those who did not
have these symptoms (Table 1).
Quantity Level of Urinary Thallium
Among all samples, the mean (SEM and range) of urinary
thallium in smokers, 10.16 μg/L (1.82 μg/L, 0–61.54 μg/L),
was significantly higher than in the controls, 2.39 μg/L
(0.63 μg/L, 0–23.8 μg/L) (P = 0.001, Z = 6.63). There was
a correlation between duration of smoking and thallium level
(r = 0.36, P = 0.003). Comparison of 22 ultra-light cigarette
consumers (Esse, Winston, Kent) and 34 light cigarette con-
sumers (Bahman, Boston, Zika, magna, Montana) that were
Table 1 Comparison of thallium level in smokers regarding clinical
symptoms
Clinical symptoma Positive Negative
N, mean (SE) N, mean (SE) P
Neurological
Aggression 32, 11.93 (2.8) 24, 7.8 (2.03) 0.23
Weakness 28, 11.01 (2.8) 28, 9.31 (2.4) 0.64
Tremor 25, 9.58 (2.81) 31, 10.63 (2.44) 0.77
Paresthesia 25, 8.99 (1.99) 31, 11.1 (2.90) 0.55
Fatigue 24, 8.66 (2.75) 32, 11.29 (2.46) 0.47
Headache 23, 7.01 (1.95) 33, 12.36 (2.74) 0.11
Insomnia 24, 14.30 (3.50) 32, 7.06 (1.68) 0.049*
Memory deficits 21, 4.6 (0.98) 35, 13.5 (2.72) 0.004**
Blurred vision 19, 11.91 (2.95) 37, 9.27 (2.32) 0.48
Depression 16, 4.08 (0.69) 40, 12.59 (2.44) 0.002**
Gastrointestinal
Constipation 18, 8.07 (2.45) 38, 11.15 (2.43) 0.37
Dermal
Scalp hair loss 21, 11.88 (3.44) 35, 9.13 (2.09) 0.49
Sweating 16, 5.68 (1.8) 40, 11.95 (2.41) 0.042*
a Small samples were omitted
* p < 0.05; ** p < 0.01
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classified based on cigarette tar showed that smokers consum-
ing ultra-light cigarette (tar found = <8 mg/cigarette) had low-
er thallium (mean rank = 19.59) than those consuming light
cigarettes (tar found > 8 mg / cigarette, mean rank = 34.26)
(P = 0.001, Z = 3.28) (Table 2).
Thallium in Smokers and Drug Users
Nine persons in the smoking group were also consumers of
opium and opium residues. The thallium level in this group of
combined abuse consumers was statistically higher than the
mean in other smokers, viz. 37.5 μg/L ± 13.09 μg/L vs.
4.93 μg/L ± 4.45 μg/L (P = 0.001, Z = 4.67). Upon excluding
the 9 abusers of opium and opium residues from the smoker
group, the thallium level of smokers was significantly higher
than that of nonsmokers, viz. 4.93 μg/L ± 4.45 μg/L vs.
2.39 μg/L ± 0.63 μg/L) (t = 2.79, P = 0.006) (Table 3).
Multiple Regression Analysis
In cigarette smokers, linear regression results showed that
about 80 percentile of thallium rate’s variance is explained
with opioid abuse, insomnia, and COPD variables.
Correlation coefficient and linear regression model results
are shown in Tables 4 and 5.
Discussion
The results showed that urine thallium levels in smokers (mean
about 5 μg/L) with no history of drug abuse were significantly
higher than in nonsmokers. The relatively small thallium
amounts in nonsmokers may be due to uptake from natural
environment, crops, fruit, and livestock that enters the human
body through food cycle [31]. Karbuska [31] reported that
thallium levels are higher in hard water due to its high solubil-
ity compared to other heavy metals. The thallium levels in the
patients with combined abuse of cigarettes and narcotics were
in average seven times higher than in the other smokers. Our
observations were consistent with the results from the Agency
of Toxic Substances and Disease Registry that reported two
times higher thallium levels in smokers than in nonsmokers
[26]. Also, Ghaderi et al. [24] reported urinary thallium of drug
abusers about 20 times higher than the levels in their group of
healthy people with a mean of 1 μg/L. The content of heavy
metals such as lead and thallium in abused drugs have been
studied [24, 25, 32–37], and there are reports of poisoning by
thallium due to use of illegal drugs (opium, opium residues,
and heroin) in Iran [24, 25]. Higher levels of urinary thallium
among smokers consuming opium and opium residues are
likely due to added impurities to the illegal drugs, apparently
representing a significant health hazard [24, 38].
Tobacco leaves are widely used in order to manufacture
cigarettes. Numerous studies have shown heavy metals such
as zinc, cobalt, nickel, lead, cadmium, and thallium in ciga-
rettes and cigarette filters [6, 39–43]. The toxicity of cigarette
smoke is influenced (determined) by its tar amount.
Comparison between ultra-light cigarette consumers (less than
8 mg tar) and light consumers (higher than 8 mg tar) in this
study showed that lower thallium level was present in the
urine of ultra-light cigarette consumers. Other studies have
confirmed that cigarettes with higher tar levels had higher
content of toxic metals such as thallium [6, 44]. The toxic
smoke enters into the body through the lungs and stomach
[45], and these compounds are slowly eliminated via the urine
and stool [26]. High levels of toxic metals in smoke from
electronic cigarettes have also been reported, in some cases
[46, 47]. Heavy metals of cigarette smoke enter easily into the
human respiratory system and result in a variety of symptoms
both from the airways and the heart [7, 8]. The relationship
between long-term smoking and thallium levels confirms the
previous data on tissue retention of thallium and other heavy
metals [15].
The most common clinical symptoms in the present study
included aggressiveness, weakness, hair loss, sweating, con-
stipation, and abdominal pain, which were essentially in




Groups Smokers (n = 56) 10.16 (1.82) 0–61.54 6.63 (Z) 0.001
Control (n = 53) 2.39 (0.63) 0–23.8
Brands
Iranian (n = 29) 9.37 (2.1) 5.07–13.67 0.44 (t) 0.65




5.02 (1.83) 1.21–8.83 3.28 (Z) 0.001
Light (n = 34) 13.49 (2.63) 8.13–18.85
Table 3 Thallium in smokers and drug users
Variables Number Mean (SD) Value P
Opium and opium residues use
Yes 9 37.5 (13.09) 4.67 (Z) 0.001
No 47 4.93 (4.45)
Hookah smoking
Yes 20 12.73 (3.3) 1.05 (t) 0.299
No 36 8.73 (2.17)
COPD diagnosis
Yes 11 17.77 (6.14) 0.88 (Z) 0.375
No 45 8.30 (1.64)
Examining of Thallium in Cigarette Smokers 227
accordance with the previous studies that reported
polyneuropathy, muscle weakness, abdominal pain, and hair
loss [15, 48–50]. However, here, it should be taken into ac-
count that smokers are exposed to a variety of toxic sub-
stances, and combined abuse with narcotics may not have
been correctly stated by all patients. Neuropsychological ef-
fects of thallium exposure have been reported previously [51],
with depression [52], memory deficits [24, 53], and sleep dis-
orders [54]. Also, 6% of smokers had experienced seizures,
apparently resulting from combination with tramadol abuse or
illegal drugs [55–58].
Generally, as mentioned earlier, results showed that opioid
abuse, insomnia, and COPD were variables that together
strongly predict the majority of thallium level variance in
smokers. This is in line with the results of the previous studies,
urinary thallium level in opioid abusers [24], smoking and
COPD [59], and thallium and insomnia [60].
Counterfeit cigarettes on Iranian markets are among the
determinants of heavy metal content of cigarettes. Sixty per-
cent of Iranian smokers in Tehran prefer foreign brands. And
counterfeit foreign brands are prevalent among Iranian
smokers [61]. Several studies have shown the presence of
heavy metals in different brands of cigarettes [6, 41, 62–65].
A comparative study by Pappas et al. on original and counter-
feit brands of cigarettes manufactured in the USA showed that
cadmium, lead, and thallium levels were higher in counterfeit
brands compared to those in original brands [6]. The need for
governmental monitoring and control over major thallium
sources including cigarettes can reduce the heavy metal expo-
sure of the population. Increasing awareness in our communi-
ty about cigarette tar of various brands can be part of these
policies. Another approach to reduce the burden of these
health effects is to apply taxes and increase prices of such
drugs and tobacco [66].
Conclusions
Thallium and other toxic metals, e.g., lead and arsenic, accu-
mulate in the body. Increased biological levels of these metals
following cigarette smoking are significant and represent a
health hazard not only for smokers but also for people who
are exposed passively. Although in smokers, individuals that
have opioid abuse, insomnia, and COPD are in high risk of
thallium toxicity and should be checked for medical health in
medical settings. Cigarette smoke is carcinogenic, and long-
term abuse may also result in undesired effects on the airways,
heart, and brain. In accordance with this, tobacco control pol-
icies should be given high priority. Tobacco control will also
reduce the burden of toxic heavy metals in the population.
Correct information by media on dangers of smoking and
drugs, and their contaminations with toxic metals, are essen-
tial for public health.
Limitations
Cause-effect relationships between toxic metal exposure in
smokers and the reported symptoms among this group
cannot be confirmed by the data presented here. It should
be taken into account that smokers are exposed to a vari-
ety of toxic substances, and the combined abuse with
narcotics may be more usual than our obtained informa-
tion’s indicate. Further studies are important to identify
causative factors for the relatively high frequency of neu-
rological and gastrointestinal symptoms in smoking
individuals.
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Table 5 Results of multiple regression model analysis (urinary














0.882 0.774 6.50 14.17 0.001
2 Insomnia 0.898 0.798 6.14 2.60 0.012
3 COPD 0.907 0.812 5.92 2.33 0.031
Table 4 Correlation coefficients between effective variables on thallium urinary in group cigarette smoking (n = 56)
Variables Age Using duration year Using daily Opioid abuse Depression Sweating Insomnia Tar rate COPD
Urinary thallium 0.43** 0.53** 0.21 0.88** 0.28* 0.20 0.26* 0.30* 0.27*
* p < 0.05; ** p < 0.01
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